留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

受体酪氨酸激酶Axl及其配体Gas6与肝细胞癌的关系

吴雨 钱平安 范兴良 祝峻峰

吴雨, 钱平安, 范兴良, 等. 受体酪氨酸激酶Axl及其配体Gas6与肝细胞癌的关系[J]. 临床肝胆病杂志, 2021, 37(1): 184-187. DOI: 10.3969/j.issn.1001-5256.2021.01.040
引用本文: 吴雨, 钱平安, 范兴良, 等. 受体酪氨酸激酶Axl及其配体Gas6与肝细胞癌的关系[J]. 临床肝胆病杂志, 2021, 37(1): 184-187. DOI: 10.3969/j.issn.1001-5256.2021.01.040
WU Y, QIAN PA, FAN XL, et al. Research advances in the association of the tyrosine kinase receptor Axl and its ligand Gas6 with hepatocellular carcinoma [J]. J Clin Hepatol, 2021, 37(1): 184-187. DOI: 10.3969/j.issn.1001-5256.2021.01.040
Citation: WU Y, QIAN PA, FAN XL, et al. Research advances in the association of the tyrosine kinase receptor Axl and its ligand Gas6 with hepatocellular carcinoma [J]. J Clin Hepatol, 2021, 37(1): 184-187. DOI: 10.3969/j.issn.1001-5256.2021.01.040

受体酪氨酸激酶Axl及其配体Gas6与肝细胞癌的关系

DOI: 10.3969/j.issn.1001-5256.2021.01.040
基金项目: 

上海市科学技术委员会科研计划项目 17401933600

上海市中医药新兴交叉学科资助计划 中医分子肝病学2017—2020

促进市级医院临床技能与临床创新能力三年行动计划项目 16CR3075B

中医优势病种培育项目 zybz-2017012

详细信息
    作者简介:

    吴雨(1988—),女,博士,主治医师,从事中医药防治慢性肝病的临床和基础研究

    通讯作者:

    祝峻峰,zhujftongling@163.com

  • 作者贡献声明:吴雨拟定写作思路,撰写论文及修改;钱平安、范兴良参与资料收集;祝峻峰指导文章修改。
  • 中图分类号: R735.7

Research advances in the association of the tyrosine kinase receptor Axl and its ligand Gas6 with hepatocellular carcinoma

  • 摘要: 受体酪氨酸激酶Axl作为酪氨酸激酶受体之一,是上皮-间质转化的重要下游调节剂,与配体Gas6蛋白结合,通过激活下游信号转导途径,与肝细胞癌的血管侵袭、肿瘤转移和复发以及较低的存活率密切相关。目前针对Gas6/Axl信号通路的研究证实,Axl抑制剂在肝癌治疗中具有重要作用,是潜在的肝癌治疗靶点。主要介绍了Axl及配体Gas6与肝癌发生、发展的关系及在肝癌诊断和治疗中的应用,为早期诊断肝癌及抗癌治疗的临床研究提供新思路。
  • [1] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): e359-e386. DOI: 10.1002/ijc.29210
    [2] REICHL P, DENGLER M, van ZIJL F, et al. Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma[J]. Hepatology, 2015, 61(3): 930-941. DOI: 10.1002/hep.27492
    [3] HOLSTEIN E, BINDER M, MIKULITS W. Dynamics of Axl receptor shedding in hepatocellular carcinoma and its implication for theranostics[J]. Int J Mol Sci, 2018, 19(12): 4111. DOI: 10.3390/ijms19124111
    [4] LEMKE G. Biology of the TAM receptors[J]. Cold Spring Harb Perspect Biol, 2013, 5(11): a009076. DOI: 10.1101/cshperspect.a009076
    [5] PAOLINO M, PENNINGER JM. The role of TAM family receptors in immune cell function: Implications for cancer therapy[J]. Cancers (Basel), 2016, 8(10): 97. DOI: 10.3390/cancers8100097
    [6] GRAHAM DK, DERYCKERE D, DAVIES KD, et al. The TAM family: Phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer[J]. Nat Rev Cancer, 2014, 14(12): 769-785. DOI: 10.1038/nrc3847
    [7] LINGER RM, KEATING AK, EARP HS, et al. TAM receptor tyrosine kinases: Biologic functions, signaling, and potential therapeutic targeting in human cancer[J]. Adv Cancer Res, 2008, 100: 35-83. DOI: 10.1016/S0065-230X(08)00002-X
    [8] YTTERSIAN SLETTA K, TVEITARÅS MK, LU N, et al. Oxygen-dependent regulation of tumor growth and metastasis in human breast cancer xenografts[J]. PLoS One, 2017, 12(8): e0183254. DOI: 10.1371/journal.pone.0183254
    [9] RANKIN EB, FUH KC, CASTELLINI L, et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET[J]. Proc Natl Acad Sci U S A, 2014, 111(37): 13373-13378. DOI: 10.1073/pnas.1404848111
    [10] WANG W, JIA WD, HU B, et al. RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma[J]. Oncotarget, 2017, 8(16): 26434-26447. DOI: 10.18632/oncotarget.15507
    [11] XU MZ, CHAN SW, LIU AM, et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma[J]. Oncogene, 2011, 30(10): 1229-1240. DOI: 10.1038/onc.2010.504
    [12] BEN-BATALLA I, SCHULTZE A, WROBLEWSKI M, et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma[J]. Blood, 2013, 122(14): 2443-2452. DOI: 10.1182/blood-2013-03-491431
    [13] RANKIN EB, GIACCIA AJ. The receptor tyrosine kinase AXL in cancer progression[J]. Cancers (Basel), 2016, 8(11): 103. DOI: 10.3390/cancers8110103
    [14] LEE HJ, JENG YM, CHEN YL, et al. Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma[J]. Carcinogenesis, 2014, 35(4): 769-775. DOI: 10.1093/carcin/bgt372
    [15] ANTONY J, HUANG RY. AXL-driven EMT state as a targetable conduit in cancer[J]. Cancer Res, 2017, 77(14): 3725-3732. DOI: 10.1158/0008-5472.CAN-17-0392
    [16] CICCHINI C, AMICONE L, ALONZI T, et al. Molecular mechanisms controlling the phenotype and the EMT/MET dynamics of hepatocyte[J]. Liver Int, 2015, 35(2): 302-310. DOI: 10.1111/liv.12577
    [17] TAM WL, WEINBERG RA. The epigenetics of epithelial-mesenchymal plasticity in cancer[J]. Nat Med, 2013, 19(11): 1438-1449. DOI: 10.1038/nm.3336
    [18] PATTABIRAMAN DR, WEINBERG RA. Tackling the cancer stem cells - what challenges do they pose?[J]. Nat Rev Drug Discov, 2014, 13(7): 497-512.
    [19] FAN QM, JING YY, YU GF, et al. Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma[J]. Cancer Lett, 2014, 352(2): 160-168. DOI: 10.1016/j.canlet.2014.05.008
    [20] ZHOU JN, ZENG Q, WANG HY, et al. MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4[J]. Hepatology, 2015, 62(3): 801-815. DOI: 10.1002/hep.27887
    [21] GIANNELLI G, KOUDELKOVA P, DITURI F, et al. Role of epithelial to mesenchymal transition in hepatocellular carcinoma[J]. J Hepatol, 2016, 65(4): 798-808. DOI: 10.1016/j.jhep.2016.05.007
    [22] ZHU AX. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: Current status and future perspectives[J]. Semin Oncol, 2012, 39(4): 493-502. DOI: 10.1053/j.seminoncol.2012.05.014
    [23] PRIETO AL, WEBER JL, LAI C. Expression of the receptor protein-tyrosine kinases Tyro-3, Axl, and mer in the developing rat central nervous system[J]. J Comp Neurol, 2000, 425(2): 295-314. DOI: 10.1002/1096-9861(20000918)425:2<295::AID-CNE11>3.0.CO;2-G
    [24] VERMA A, WARNER SL, VANKAYALAPATI H, et al. Targeting Axl and Mer kinases in cancer[J]. Mol Cancer Ther, 2011, 10(10): 1763-1773. DOI: 10.1158/1535-7163.MCT-11-0116
    [25] ASIEDU MK, BEAUCHAMP-PEREZ FD, INGLE JN, et al. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells[J]. Oncogene, 2014, 33(10): 1316-1324. DOI: 10.1038/onc.2013.57
    [26] ZHANG Z, LEE JC, LIN L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer[J]. Nat Genet, 2012, 44(8): 852-860. DOI: 10.1038/ng.2330
    [27] WILSON C, YE X, PHAM T, et al. AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs[J]. Cancer Res, 2014, 74(20): 5878-5890. DOI: 10.1158/0008-5472.CAN-14-1009
    [28] CICHON' MA, SZENTPETERY Z, CALEY MP, et al. The receptor tyrosine kinase Axl regulates cell-cell adhesion and stemness in cutaneous squamous cell carcinoma[J]. Oncogene, 2014, 33(32): 4185-4192. DOI: 10.1038/onc.2013.388
    [29] BROWN M, BLACK JR, SHARMA R, et al. Gene of the month: Axl[J]. J Clin Pathol, 2016, 69(5): 391-397. DOI: 10.1136/jclinpath-2016-203629
    [30] GIANNELLI G, VILLA E, LAHN M. Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma[J]. Cancer Res, 2014, 74(7): 1890-1894. DOI: 10.1158/0008-5472.CAN-14-0243
    [31] van der MEER JH, van der POLL T, van't VEER C. TAM receptors, Gas6, and protein S: Roles in inflammation and hemostasis[J]. Blood, 2014, 123(16): 2460-2469. DOI: 10.1182/blood-2013-09-528752
    [32] AITKEN A. Post-translational modification of 14-3-3 isoforms and regulation of cellular function[J]. Semin Cell Dev Biol, 2011, 22(7): 673-680. DOI: 10.1016/j.semcdb.2011.08.003
    [33] CHOI JE, HUR W, JUNG CK, et al. Silencing of 14-3-3ζ over-expression in hepatocellular carcinoma inhibits tumor growth and enhances chemosensitivity to cis-diammined dichloridoplatium[J]. Cancer Lett, 2011, 303(2): 99-107. DOI: 10.1016/j.canlet.2011.01.015
    [34] HUANG XY, KE AW, SHI GM, et al. αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma[J]. Hepatology, 2013, 57(6): 2235-2247. DOI: 10.1002/hep.26255
    [35] LI Y, JIA L, REN D, et al. Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma[J]. IUBMB Life, 2014, 66(7): 507-518. DOI: 10.1002/iub.1285
    [36] STENHOFF J, DAHLBÄCK B, HAFIZI S. Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts[J]. Biochem Biophys Res Commun, 2004, 319(3): 871-878. DOI: 10.1016/j.bbrc.2004.05.070
    [37] HECTOR A, MONTGOMERY EA, KARIKARI C, et al. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma[J]. Cancer Biol Ther, 2010, 10(10): 1009-1018. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025816/
    [38] REICHL P, MIKULITS W. Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review)[J]. Oncol Rep, 2016, 36(2): 613-625.
    [39] HU B, TIAN X, SUN J, et al. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: A meta-analysis[J]. Int J Mol Sci, 2013, 14(12): 23559-23580.
    [40] EKMAN C, STENHOFF J, DAHLBÄCK B. Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood[J]. J Thromb Haemost, 2010, 8(4): 838-844. DOI: 10.1111/j.1538-7836.2010.03752.x/full
    [41] REICHL P, FANG M, STARLINGER P, et al. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma[J]. Int J Cancer, 2015, 137(2): 385-394.
    [42] SHEN Y, CHEN X, HE J, et al. Axl inhibitors as novel cancer therapeutic agents[J]. Life Sci, 2018, 198: 99-111.
    [43] PINATO DJ, BROWN MW, TROUSIL S, et al. Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma[J]. Br J Cancer, 2019, 120(5): 512-521.
    [44] WU X, LIU X, KOUL S, et al. AXL kinase as a novel target for cancer therapy[J]. Oncotarget, 2014, 5(20): 9546-9563. http://europepmc.org/articles/pmc4259419/
  • 加载中
计量
  • 文章访问数:  88
  • HTML全文浏览量:  24
  • PDF下载量:  8
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-06-07
  • 修回日期:  2020-08-17
  • 刊出日期:  2021-01-18
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回